Interestingly, a recent study reported no association between ASCT2 expression and the response to the inhibitor V9302 [28], suggesting that the extent of glutamine dependence in SS may be a more critical determinant of drug efficacy. Here, SLC1A5 is linked to synovial sarcoma.